Affiliation:
1. Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2. Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong 999077, China
3. China Mengniu Dairy Company Limited, Hohhot 010000, China
4. School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong 999077, China
Abstract
NASH (non-alcoholic steatohepatitis) is a severe liver disease characterized by hepatic chronic inflammation that can be associated with the gut microbiota. In this study, we explored the therapeutic effect of Gynostemma pentaphyllum extract (GPE), a Chinese herbal extract, on methionine- and choline-deficient (MCD) diet-induced NASH mice. Based on the peak area, the top ten compounds in GPE were hydroxylinolenic acid, rutin, hydroxylinoleic acid, vanillic acid, methyl vanillate, quercetin, pheophorbide A, protocatechuic acid, aurantiamide acetate, and iso-rhamnetin. We found that four weeks of GPE treatment alleviated hepatic confluent zone inflammation, hepatocyte lipid accumulation, and lipid peroxidation in the mouse model. According to the 16S rRNA gene V3–V4 region sequencing of the colonic contents, the gut microbiota structure of the mice was significantly changed after GPE supplementation. Especially, GPE enriched the abundance of potentially beneficial bacteria such as Akkerrmansia and decreased the abundance of opportunistic pathogens such as Klebsiella. Moreover, RNA sequencing revealed that the GPE group showed an anti-inflammatory liver characterized by the repression of the NF-kappa B signaling pathway compared with the MCD group. Ingenuity Pathway Analysis (IPA) also showed that GPE downregulated the pathogen-induced cytokine storm pathway, which was associated with inflammation. A high dose of GPE (HGPE) significantly downregulated the expression levels of the tumor necrosis factor-α (TNF-α), myeloid differentiation factor 88 (Myd88), cluster of differentiation 14 (CD14), and Toll-like receptor 4 (TLR4) genes, as verified by real-time quantitative PCR (RT-qPCR). Our results suggested that the therapeutic potential of GPE for NASH mice may be related to improvements in the intestinal microenvironment and a reduction in liver inflammation.
Funder
National Natural Science Foundation of China
Open Project of Translational Chinese Medicine Key Laboratory of Sichuan Province
Shanghai Collaborative Innovation Center for Chronic Disease Prevention and Health Services
Reference63 articles.
1. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis;Manne;Clin. Liver Dis.,2018
2. Mechanisms of NAFLD development and therapeutic strategies;Friedman;Nat. Med.,2018
3. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention;Huang;Nat. Rev. Gastroenterol. Hepatol.,2021
4. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018
5. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis;Harrison;N. Engl. J. Med.,2024